Literature DB >> 26770493

RASAL2 inhibited the proliferation and metastasis capability of nasopharyngeal carcinoma.

Zhongliang Wang1, Jiang Wang1, Yue Su1, Zhen Zeng1.   

Abstract

Recently, RASAL2 has been found to function as a tumor and metastasis suppressor. RASAL2 inhibited tumor growth, progression, and metastasis in several cancers. However, the regulatory effect of RASAL2 in NPC still remains unclear. The purpose of this paper was to identify the role of RASAL2 in the metastasis of NPC. The expression of RASAL2 in human NPC was obviously down-regulated by real-time PCR analysis. Furthermore, knock-down of RASAL2 with siRNA treatment resulted in a promotion of cell proliferation and migration in vitro. Additionally, transwell analysis results revealed that the number of invasion cells was increased of cells treated with RASAL2 siRNA. We further explored the mechanism and demonstrated that the down-regulated RASAL2 promoted migration and invasion via EMT induction with E-cadherin decreased expression and vimentin, N-cadherin, and Snail increased expression in NPC cells.In conclusion, RASAL2 inhibited the proliferation and metastasis capability of NPC cells.

Entities:  

Keywords:  EMT; NPC; RASAL2; metastasis; proliferation; tumor suppressor

Year:  2015        PMID: 26770493      PMCID: PMC4694393     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  28 in total

Review 1.  EMT: when epithelial cells decide to become mesenchymal-like cells.

Authors:  Raghu Kalluri
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

2.  Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Zhe Zhang; Di Sun; Do Nguyen Van; Anzhou Tang; Lifu Hu; Guangwu Huang
Journal:  Int J Cancer       Date:  2007-01-01       Impact factor: 7.396

3.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

Authors:  A W Lee; Y F Poon; W Foo; S C Law; F K Cheung; D K Chan; S Y Tung; M Thaw; J H Ho
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.

Authors:  L-M Cai; X-M Lyu; W-R Luo; X-F Cui; Y-F Ye; C-C Yuan; Q-X Peng; D-H Wu; T-F Liu; E Wang; F-M Marincola; K-T Yao; W-Y Fang; H-B Cai; X Li
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

Review 5.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 6.  Inflammation linking EMT and cancer stem cells.

Authors:  Chenchen Zhou; Jeffrey Liu; Yaling Tang; Xinhua Liang
Journal:  Oral Oncol       Date:  2012-07-04       Impact factor: 5.337

7.  Design of a prognostic index score for metastatic nasopharyngeal carcinoma.

Authors:  Y K Ong; D M Heng; B Chung; S S Leong; J Wee; K W Fong; T Tan; E H Tan
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

8.  Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma.

Authors:  T Horikawa; T Yoshizaki; S Kondo; M Furukawa; Y Kaizaki; J S Pagano
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

9.  ZNF488 Enhances the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma Via the Wnt Signaling Pathway Involving Epithelial Mesenchymal Transition.

Authors:  Dan Zong; Li Yin; Qian Zhong; Wen-Jie Guo; Jian-Hua Xu; Ning Jiang; Zhi-Rui Lin; Man-Zhi Li; Ping Han; Lin Xu; Xia He; Mu-Sheng Zeng
Journal:  Cancer Res Treat       Date:  2015-03-12       Impact factor: 4.679

10.  Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.

Authors:  M Aga; G L Bentz; S Raffa; M R Torrisi; S Kondo; N Wakisaka; T Yoshizaki; J S Pagano; J Shackelford
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

View more
  11 in total

1.  Long noncoding RNA SMAD5-AS1 acts as a microRNA-106a-5p sponge to promote epithelial mesenchymal transition in nasopharyngeal carcinoma.

Authors:  Ying-Juan Zheng; Jing-Yi Zhao; Tian-Song Liang; Ping Wang; Juan Wang; Dao-Ke Yang; Zhang-Suo Liu
Journal:  FASEB J       Date:  2019-09-26       Impact factor: 5.191

Review 2.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

3.  The expression and function of RASAL2 in renal cell carcinoma angiogenesis.

Authors:  Ke Hui; Yangyang Yue; Shiqi Wu; Yanan Gu; Bing Guan; Xinyang Wang; Jer-Tsong Hsieh; Luke S Chang; Dalin He; Kaijie Wu
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

4.  miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer.

Authors:  Jie Xiong; Shigang Xing; Zheng Dong; Lei Niu; Qinghua Xu; Yusheng Li; Pingyi Liu; Peixia Yang
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

5.  RASAL2 suppresses the proliferative and invasive ability of PC3 prostate cancer cells.

Authors:  Krishma Tailor; Joseph Paul; Somiranjan Ghosh; Namita Kumari; Bernard Kwabi-Addo
Journal:  Oncotarget       Date:  2021-12-21

6.  The Role of hsa-miR-21 and Its Target Genes Involved in Nasopharyngeal Carcinoma.

Authors:  Thuan Duc Lao; Minh Trong Quang; Thuy Ai Huyen Le
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

7.  PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.

Authors:  Yong Bao; Christopher Qian; Meng-Yue Liu; Fei Jiang; Xiaoxiao Jiang; Huijuan Liu; Zhuqing Zhang; Fanghui Sun; Ningwei Fu; Zhaoyuan Hou; Ya Ke; Yan Li; Zhong-Ming Qian
Journal:  Autophagy       Date:  2021-02-24       Impact factor: 16.016

8.  RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.

Authors:  Ke Hui; Yang Gao; Jun Huang; Shan Xu; Bin Wang; Jin Zeng; Jinhai Fan; Xinyang Wang; Yangyang Yue; Shiqi Wu; Jer-Tsong Hsieh; Dalin He; Kaijie Wu
Journal:  Cell Death Dis       Date:  2017-02-09       Impact factor: 8.469

Review 9.  Epigenetic changes in fibroblasts drive cancer metabolism and differentiation.

Authors:  Rajeev Mishra; Subhash Haldar; Surabhi Suchanti; Neil A Bhowmick
Journal:  Endocr Relat Cancer       Date:  2019-12       Impact factor: 5.678

Review 10.  RASAL2 Plays Inconsistent Roles in Different Cancers.

Authors:  Bolun Zhou; Wei Zhu; Xingjun Jiang; Caiping Ren
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.